Cancer vaccine therapy using genetically modified induced pluripotent stem cell-derived dendritic cells expressing the TAA gene.

我们从iPS细胞中培养出诱导多能干细胞来源的树突状细胞(IPSDCs)，并比较了IPSDCs与骨髓来源的DCs(BMDCs)的成熟能力以及IPSDCs向淋巴结迁移的能力。我们将hgp100基因转导入树突状细胞，并用转基因的树突状细胞免疫小鼠。我们的结果表明，IPSDCs在成熟和迁移方面与BMDCs具有相同的能力。此外，用转基因IPSDCs免疫的小鼠产生了hgp100特异性CTL。这些CTL对B16细胞的杀伤作用与BMDCs一样高。此外，用转基因IPSDCs接种疫苗的治疗效果与接种BMDCs疫苗一样高。我们的研究表明，在肿瘤相关抗原特异性治疗性抗肿瘤免疫方面，转基因IPSDCs与BMDCs具有相同的能力。

We developed the induced pluripotent stem cell-derived dendritic cells DCs (iPSDCs) from iPS cells and examined the capacity for maturation of iPSDCs compared to that of bone marrow-derived DCs (BMDCs) in addition to the capacity for migration of iPSDCs to lymph nodes. We adenovirally transduced the hgp100 gene, natural tumor antigens, into DCs and immunized mice once with the genetically modified DCs. Our results showed that iPSDCs have an equal capacity to BMDCs in terms of maturation and migration. Furthermore, hgp100-specific CTLs were generated in mice immunized with genetically modified iPSDCs. These CTLs exhibited as high a level of cytotoxicity against B16 cells as BMDCs. Moreover, vaccination with the genetically modified iPSDCs achieved as high a level of therapeutic efficacy as vaccination with BMDCs. Our study clarified that genetically modified iPSDCs have an equal capacity to BMDCs in terms of tumor-associated antigen specific therapeutic antitumor immunity.